Education
About Us
Working with TipRanks
Follow Us
Iovance Biotherapeutics Inc (GB:0JDK)
LSE:0JDK
Earnings Data
Report Date
Mar 03, 2026TBA (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.19Last Year’s EPS
-0.26Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Q3 2025
Earnings Call Date:Nov 06, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
The earnings call was largely positive, highlighting significant revenue growth, successful strategic restructuring, and promising clinical data in lung cancer. However, challenges remain in expense management, global market expansion, and community ATC adoption.Company Guidance
Revenue Growth and Improved Margins
Third quarter revenue grew 13% over the prior quarter, reaching approximately $68 million. Gross margin improved to 43% following strategic restructuring and cost optimization.
Expansion of Academic and Community ATCs
Iovance expanded its network to include new academic and multiple community ATCs, with initial patients being treated and earlier patient referrals driving growth.
Positive Clinical Data in Lung Cancer
Interim clinical data for previously treated non-squamous non-small cell lung cancer showed a 26% objective response rate and median duration of response not reached at over 25 months.
Successful Manufacturing Transition Plans
Iovance is centralizing manufacturing at its internal facility, expecting significant cost savings and improved gross margin as operations transition in early 2026.
Strong Cash Position
The cash position was approximately $307 million as of September 30, expected to fund operations into the second quarter of 2027.
GB:0JDK Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GB:0JDK Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 06, 2025 | $1.79 | $2.46 | +37.17% |
Aug 07, 2025 | $2.63 | $2.00 | -23.93% |
May 08, 2025 | $3.30 | $1.74 | -47.42% |
Feb 27, 2025 | $5.49 | $4.31 | -21.51% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Iovance Biotherapeutics Inc (GB:0JDK) report earnings?
Iovance Biotherapeutics Inc (GB:0JDK) is schdueled to report earning on Mar 03, 2026, TBA (Confirmed).
What is Iovance Biotherapeutics Inc (GB:0JDK) earnings time?
Iovance Biotherapeutics Inc (GB:0JDK) earnings time is at Mar 03, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Iovance Biotherapeutics Inc stock?
The P/E ratio of Iovance Biotherapeutics is N/A.
What is GB:0JDK EPS forecast?
GB:0JDK EPS forecast for the fiscal quarter 2025 (Q4) is -0.19.